SCHEMBL20547206

SCHEMBL20547206

Cc1ccc(CNc2nc(Cl)nc3c2ncn3C2CCCCO2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ YTHDC1 Q96MU7 1/20 0.68
▸ NPC1 O15118 2/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ CTSL P07711 1/20 0.48
▸ CDK1 P06493 2/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CCNE2 O96020 1/20 0.47
▸ CCNE1 P24864 1/20 0.47
▸ CDK2 P24941 1/20 0.47
▸ ADORA3 P0DMS8 4/20 0.47
▸ ADORA1 P30542 2/20 0.47
▸ ADORA2A P29274 1/20 0.47
▸ TSHR P16473 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ GMNN O75496 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29659560 1.00 YTHDC1 (0.68) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL20547202 0.90 YTHDC1 (0.65) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL1501479 0.90 NPC1 (0.73) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL29659561 0.90 NPC1 (0.73) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL29659669 0.90 YTHDC1 (0.64) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL5763160 0.90 YTHDC1 (0.64) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL30410510 0.89 NPC1 (0.60) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL20547443 0.88 YTHDC1 (0.62) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL29659511 0.88 YTHDC1 (0.62) YTHDC1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL20547488 0.87 YTHDC1 (0.60) YTHDC1NPC1RAB9ASMN1; SMN2CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643413-B2 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2023-05-09 — — US disclosed
EP-3615535-B1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS UNIV PALACKEHO (CZ) 2022-06-15 — — EP disclosed
US-20200157105-A1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-05-21 — — US disclosed
EP-3615535-A1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS Univerzita Palackého v Olomouci (CZ) 2020-03-04 — — EP disclosed
WO-2018196893-A1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157105-A1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS ADORA2A, UNG, P2RY6 YTHDC1 1391/4885NPC1 3725/4885RAB9A 1831/4885
US-11643413-B2 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders ADORA2A, UNG, P2RY6 YTHDC1 1391/4885NPC1 3725/4885RAB9A 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback